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BACKGROUND
Olaparib has shown significant clinical benefit as maintenance therapy in women 
with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect 
of combining maintenance olaparib and bevacizumab in patients regardless of 
BRCA mutation status is unknown.
METHODS
We conducted a randomized, double-blind, international phase 3 trial. Eligible 
patients had newly diagnosed, advanced, high-grade ovarian cancer and were hav-
ing a response after first-line platinum–taxane chemotherapy plus bevacizumab. 
Patients were eligible regardless of surgical outcome or BRCA mutation status. 
Patients were randomly assigned in a 2:1 ratio to receive olaparib tablets (300 mg 
twice daily) or placebo for up to 24 months; all the patients received bevacizumab 
at a dose of 15 mg per kilogram of body weight every 3 weeks for up to 15 months 
in total. The primary end point was the time from randomization until investiga-
tor-assessed disease progression or death.
RESULTS
Of the 806 patients who underwent randomization, 537 were assigned to receive 
olaparib and 269 to receive placebo. After a median follow-up of 22.9 months, the 
median progression-free survival was 22.1 months with olaparib plus bevacizumab 
and 16.6 months with placebo plus bevacizumab (hazard ratio for disease progres-
sion or death, 0.59; 95% confidence interval [CI], 0.49 to 0.72; P<0.001). The haz-
ard ratio (olaparib group vs. placebo group) for disease progression or death was 
0.33 (95% CI, 0.25 to 0.45) in patients with tumors positive for homologous-
recombination deficiency (HRD), including tumors that had BRCA mutations 
(median progression-free survival, 37.2 vs. 17.7 months), and 0.43 (95% CI, 0.28 
to 0.66) in patients with HRD-positive tumors that did not have BRCA mutations 
(median progression-free survival, 28.1 vs. 16.6 months). Adverse events were con-
sistent with the established safety profiles of olaparib and bevacizumab.
CONCLUSIONS
In patients with advanced ovarian cancer receiving first-line standard therapy in-
cluding bevacizumab, the addition of maintenance olaparib provided a signifi-
cant progression-free survival benefit, which was substantial in patients with 
HRD-positive tumors, including those without a BRCA mutation. (Funded by 
ARCAGY Research and others; PAOLA-1 ClinicalTrials.gov number, NCT02477644.)
A BS TR AC T
Olaparib plus Bevacizumab as First-Line 
Maintenance in Ovarian Cancer
I. Ray-Coquard, P. Pautier, S. Pignata, D. Pérol, A. González-Martín, R. Berger, 
K. Fujiwara, I. Vergote, N. Colombo, J. Mäenpää, F. Selle, J. Sehouli, D. Lorusso, 
E.M. Guerra Alía, A. Reinthaller, S. Nagao, C. Lefeuvre-Plesse, U. Canzler, 
G. Scambia, A. Lortholary, F. Marmé, P. Combe, N. de Gregorio, M. Rodrigues, 
P. Buderath, C. Dubot, A. Burges, B. You, E. Pujade-Lauraine, and P. Harter,  
for the PAOLA-1 Investigators* 
Original Article
n engl j med 381;25 nejm.org December 19, 2019 2417
Olaparib plus Bevacizumab in Ovarian Cancer
Newly diagnosed advanced ovarian cancer is treated with curative intent. However, owing to late diagnosis with 
advanced-stage disease, the vast majority of pa-
tients have a relapse (after a median of 10 to 
18 months),1,2 despite being treated with cyto-
reductive surgery and platinum-based chemo-
therapy.3
The addition of the antiangiogenic agent beva-
cizumab to carboplatin plus paclitaxel, followed 
by bevacizumab alone, is a standard option in 
patients with newly diagnosed advanced ovarian 
cancer.1,2,4-7 Recently, in the phase 3 SOLO1 trial, 
the poly(adenosine diphosphate–ribose) polymer-
ase (PARP) inhibitor olaparib provided a sub-
stantial progression-free survival benefit as main-
tenance monotherapy in patients with newly 
diagnosed advanced ovarian cancer whose tumors 
had a BRCA1 or BRCA2 mutation (BRCA mutation) 
and who had a complete or partial clinical re-
sponse after platinum-based chemotherapy 
(hazard ratio for disease progression or death, 
0.30; 95% confidence interval [CI], 0.23 to 0.41; 
P<0.001).8
PARP inhibitors trap PARP on DNA at sites 
of single-strand breaks, preventing the repair 
of these breaks and generating double-strand 
breaks that cannot be repaired accurately in 
tumors with homologous-recombination defi-
ciency (HRD).9 HRD is not limited to tumors 
with BRCA mutations and is present in approxi-
mately 50% of high-grade serous ovarian tu-
mors.10 Indeed, in platinum-sensitive relapsed 
ovarian cancer,11-13 PARP inhibitors are active as 
maintenance monotherapy in patients who have 
tumors without BRCA mutations, although the 
magnitude of benefit appears lower than in pa-
tients with BRCA-mutated tumors. Moreover, the 
addition of an antiangiogenic agent to a PARP 
inhibitor in phase 2 studies involving patients 
with relapsed platinum-sensitive ovarian can-
cer14-16 resulted in longer progression-free sur-
vival than the use of a PARP inhibitor alone. In 
the phase 3 PAOLA-1 (PAOLA-1/ENGOT-ov25) 
trial, we evaluated maintenance therapy with a 
PARP inhibitor (olaparib) as compared with 
placebo in patients with newly diagnosed ad-
vanced ovarian cancer who were receiving 
 chemotherapy plus bevacizumab followed by 
bevacizumab, regardless of BRCA mutation 
status.
Me thods
Patients
Eligible patients were 18 years of age or older 
and had newly diagnosed advanced (Interna-
tional Federation of Gynecology and Obstetrics 
[FIGO] stage III or IV), high-grade serous or 
endometrioid ovarian cancer, primary peritoneal 
cancer, or fallopian-tube cancer. (For details on 
the FIGO staging system, see Table S1 in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org.) Patients with 
other nonmucinous epithelial ovarian cancers 
were eligible, provided they had a deleterious 
germline BRCA1 or BRCA2 mutation. Patients were 
eligible irrespective of previous surgical outcome 
(residual macroscopic disease or no residual 
macroscopic disease after upfront or interval 
surgery). After first-line treatment with platinum–
taxane chemotherapy plus bevacizu mab, patients 
were required to have no evidence of disease or 
to have had a clinical complete or partial re-
sponse (definitions in Table 1). Patients had an 
Eastern Cooperative Oncology Group perfor-
mance status of 0 or 1 (on a 5-point scale in 
which higher numbers reflect greater disability), 
and a tumor sample had to be available for cen-
tral testing to determine BRCA mutation status. 
Details of BRCA testing and full eligibility criteria 
are provided in the Supplementary Appendix. All 
the patients provided written informed consent.
Trial Design and Intervention
The randomized, double-blind, placebo-controlled 
PAOLA-1 trial was conducted in 11 countries. 
Randomization was performed centrally with 
the use of a block design with stratification ac-
cording to the outcome of first-line treatment at 
screening and tumor BRCA status (see the Sup-
plementary Appendix). Patients were assigned 
to olaparib tablets or matching placebo tablets 
with the use of an interactive Web or voice re-
sponse system.
Patients were randomly assigned in a 2:1 ratio 
to receive olaparib (300 mg twice daily) or pla-
cebo at least 3 weeks and no more than 9 weeks 
after the last dose of chemotherapy. All the ma-
jor toxic effects that were associated with chemo-
therapy had to have resolved to grade 1 (accord-
ing to the National Cancer Institute Common 
Terminology Criteria for Adverse Events [CTCAE], 
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Characteristic
Olaparib plus 
Bevacizumab (N = 537)
Placebo plus 
Bevacizumab (N = 269)
Median age (range) — yr 61.0 (32.0–87.0) 60.0 (26.0–85.0)
ECOG performance status — no. (%)†
0 378 (70) 189 (70)
1 153 (28) 76 (28)
Missing data 6 (1) 4 (1)
Primary tumor location — no. (%)
Ovary 456 (85) 238 (88)
Fallopian tube 39 (7) 11 (4)
Peritoneum 42 (8) 20 (7)
FIGO stage — no. (%)‡
III 378 (70) 186 (69)
IV 159 (30) 83 (31)
Histologic type — no. (%)
Serous 519 (97) 253 (94)
Endometrioid 12 (2) 8 (3)
Other§ 6 (1) 8 (3)
History of cytoreductive surgery
Upfront — no. (%) 271 (50) 138 (51)
Macroscopic residual disease — no./total no. (%) 111/271 (41) 53/138 (38)
No macroscopic residual disease — no./total no. (%) 160/271 (59) 85/138 (62)
Interval — no. (%) 228 (42) 110 (41)
Macroscopic residual disease — no./total no. (%) 65/228 (29) 35/110 (32)
No macroscopic residual disease — no./total no. (%) 163/228 (71) 75/110 (68)
No surgery — no. (%) 38 (7) 21 (8)
Response after first-line chemotherapy — no. (%)
No evidence of disease¶ 290 (54) 141 (52)
Complete response‖ 106 (20) 53 (20)
Partial response** 141 (26) 75 (28)
Normal serum CA-125 level — no. (%)
Yes 463 (86) 234 (87)
No 74 (14) 34 (13)
Missing 0 1 (<1)
Deleterious tumor BRCA mutation — no. (%)
Yes 161 (30) 80 (30)
No 376 (70) 189 (70)
Tumor HRD status — no. (%)††
Positive 255 (47) 132 (49)
Negative or unknown 282 (53) 137 (51)
Negative 192 (36) 85 (32)
Unknown 90 (17) 52 (19)
Table 1. Characteristics of the Patients at Baseline.*
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version 4.03) or had to have resolved completely 
(except alopecia and peripheral neuropathy).
Administration of olaparib or placebo contin-
ued for up to 24 months from randomization or 
until disease progression (according to investi-
gators’ assessment of imaging based on the 
modified Response Evaluation Criteria in Solid 
Tumors [RECIST], version 1.1) or unacceptable 
toxic effects, whichever occurred first, as long as 
the patient had a benefit and did not meet other 
discontinuation criteria. Crossover between the 
trial groups was not planned. After discontinua-
tion of the intervention, patients could receive 
other treatments at the investigators’ discretion. 
Details of discontinuation criteria and methods 
for unblinding are provided in the Supplemen-
tary Appendix. As part of the intervention, intra-
venous bevacizumab was initiated in combina-
tion with chemotherapy and was continued after 
randomization as maintenance therapy at a dose 
of 15 mg per kilogram of body weight every 
3 weeks for a total duration of up to 15 months.
End Points and Assessments
The primary end point was the time from ran-
domization until investigator-assessed disease 
progression or death. Tumor assessment scans 
(computed tomography or magnetic resonance 
imaging) were performed at baseline and then 
every 24 weeks (or at planned visits every 12 
weeks if there was evidence of clinical progres-
sion or progression according to the serum level 
of cancer antigen 125) up to month 42 or until 
the date of data cutoff. Subgroup analyses of 
progression-free survival and a blinded indepen-
dent central review of progression-free survival 
were performed.
Secondary end points were the time from 
randomization until second disease progression 
or death, overall survival, the time until the first 
subsequent therapy or death, and the global 
health status–quality of life dimension of the 
European Organization for Research and Treat-
ment of Cancer (EORTC) Quality of Life Ques-
tionnaire (EORTC QLQ-C30; scores range from 
0 to 100, with higher scores indicating better 
health-related quality of life and with a mini-
mal clinically important difference defined as 
10 points).17 The EORTC QLQ-C30 was com-
pleted at baseline and then every 12 weeks for 
2 years or until the date of data cutoff. Adverse 
events were graded with the use of the CTCAE, 
version 4.03. Tumor HRD status was determined 
with the use of the myChoice HRD Plus assay 
(Myriad Genetic Laboratories). An HRD score of 
42 or higher indicated a positive test, and an 
HRD score of less than 42 indicated a negative 
test. Details of trial end points and analyses are 
provided in the Supplementary Appendix.
Trial Oversight
The trial was performed in accordance with the 
provisions of the Declaration of Helsinki and 
Good Clinical Practice guidelines under the aus-
pices of an independent data monitoring com-
mittee. The trial was designed by the European 
Network for Gynecological Oncological Trial 
Groups (ENGOT) lead group, Groupe d’Investi-
*  Percentages may not total 100 because of rounding. CA-125 denotes cancer antigen 125, and HRD homologous- 
recombination deficiency.
†  Eastern Cooperative Oncology Group (ECOG) performance status ranges from 0 to 5, with higher values reflecting 
greater disability.
‡  Details on the International Federation of Gynecology and Obstetrics (FIGO) staging system are provided in Table S1 
in the Supplementary Appendix.
§  “Other” was defined as clear-cell (in 2 patients assigned to olaparib plus bevacizumab), undifferentiated (in 1 patient
assigned to olaparib plus bevacizumab and 6 patients assigned to placebo plus bevacizumab), or other (in 3 patients 
assigned to olaparib plus bevacizumab and 2 patients assigned to placebo plus bevacizumab).
¶  No evidence of disease was defined as no measurable or assessable disease after cytoreductive surgery plus no radio-
logic evidence of disease and a normal CA-125 level after chemotherapy.
‖  Clinical complete response was defined as the disappearance of all measurable or assessable disease and normaliza-
tion of CA-125 levels.
**  Partial response was defined as radiologic evidence of disease, an abnormal CA-125 level, or both.
††  HRD positive was defined as a tumor BRCA mutation or an HRD score of 42 or higher on the myChoice HRD Plus 
assay (Myriad Genetic Laboratories). HRD negative was defined as an HRD score of less than 42. “Unknown” was 
defined as an inconclusive, missing, or failed test.
Table 1. (Continued.)
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gateurs Nationaux pour l’Etude des Cancers 
Ovariens, and sponsored by Association de Re-
cherche Cancers Gynécologiques (ARCAGY) Re-
search, according to the ENGOT model A (aca-
demic sponsor; details of this research model 
are provided in the Supplementary Appendix).18,19 
ARCAGY Research was responsible for oversee-
ing the collection, analysis, and interpretation 
of the data. AstraZeneca, Merck Sharp & Dohme 
(a subsidiary of Merck), and F. Hoffmann–La 
Roche were given the opportunity to review 
drafts of the manuscripts but were not asked to 
approve the final content because this was an 
academic-sponsored trial. The authors wrote the 
manuscript, with medical writing assistance 
funded by ARCAGY Research, AstraZeneca, and 
Merck Sharp & Dohme. The authors attest to the 
accuracy and completeness of the data and to 
the adherence of the trial to the protocol (avail-
able at NEJM.org).
Statistical Analysis
The trial was designed to detect a treatment ef-
fect (hazard ratio for disease progression or death) 
of 0.75, translating to an improvement in median 
progression-free survival from 15.8 months in 
the placebo group to 21.1 months in the olapa-
rib group20; 458 primary end-point events (dis-
ease progression or death) would give the trial 
more than 80% power at a two-sided signifi-
cance level of 5% to show a significant differ-
ence in progression-free survival between the 
olaparib group and the placebo group. The ran-
domization of 762 patients would result in data 
being mature once approximately 60% of the 
patients had had disease progression or had 
died; an additional 24 patients underwent ran-
domization in Japan.
All efficacy data were summarized and ana-
lyzed in the intention-to-treat population, which 
included all the patients who had undergone 
randomization, regardless of the intervention 
received. In this analysis, we used the electronic 
case-report form data set, except for the pre-
specified HRD analysis, which used the Myriad 
myChoice Plus HRD test. Safety data were sum-
marized in the safety analysis set (all patients 
who received at least one dose of olaparib or 
placebo). Analyses of health-related quality of life 
used an imputation-based approach for missing 
questionnaires.
The Kaplan–Meier method was used to esti-
mate progression-free survival, with the strati-
fied log-rank test used to assess the difference 
between the olaparib group and the placebo group. 
The hazard ratio and associated 95% confidence 
interval were calculated with the use of a strati-
fied Cox proportional-hazards model. In order 
to show consistency of the treatment effect in 
prespecified subgroups, a preplanned progression-
free survival analysis was performed in which the 
hazard ratio and 95% confidence interval were 
calculated with the use of an unstratified Cox 
model.
Analyses of secondary efficacy end points 
used a method similar to that used in the pro-
gression-free survival analysis. A hierarchical-
testing procedure was used to control for type I 
error at 5% for progression-free survival, second 
progression–free survival, and overall survival, 
in that order.
The change from baseline in the global health 
status–quality of life score was assessed with the 
use of a mixed model for repeated measures.21 
Adverse events were analyzed descriptively; an 
interim safety analysis was planned and conduct-
ed. Details of the statistical analyses are pro-
vided in the Supplementary Appendix. The statis-
tical analysis plan is available with the protocol 
at NEJM.org.
R esult s
Patients
From July 2015 through September 2017, a total 
of 806 patients underwent randomization. A to-
tal of 535 of the 537 patients assigned to olapa-
rib plus bevacizumab (olaparib group) and 267 of 
the 269 patients assigned to placebo plus beva-
cizumab (placebo group) received the trial inter-
vention; 2 patients in each group withdrew be-
fore receiving the trial intervention (Fig. S1).
The baseline characteristics were well bal-
anced between the trial groups (Table 1 and 
Tables S2 through S4). A total of 30% of the 
patients had stage IV disease, and most patients 
had no evidence of disease owing to complete 
cytoreduction or were having a complete response 
after first-line treatment. A total of 30% of the 
patients had a deleterious tumor BRCA mutation.
Efficacy
The primary analysis of investigator-assessed 
progression-free survival was performed after 
474 of 806 patients had had disease progression 
or had died (data maturity, 59%) (data cutoff, 
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March 22, 2019). The median duration of follow-
up for the primary analysis was 22.7 months 
(range, 18.0 to 27.7) in the olaparib group and 
24.0 months (range, 18.7 to 27.7) in the placebo 
group; the median duration of follow-up in the 
combined groups was 22.9 months.
The duration of investigator-assessed pro-
gression-free survival was significantly longer in 
the olaparib group than in the placebo group 
(median, 22.1 months vs. 16.6 months; hazard 
ratio for disease progression or death, 0.59; 95% 
CI, 0.49 to 0.72; P<0.001) (Fig. 1). Results of the 
analysis of progression-free survival as assessed 
by blinded independent review (Fig. S2) were 
consistent with the results of the primary analy-
sis (median, 26.1 months in the olaparib group 
and 18.3 months in the placebo group; hazard 
ratio for disease progression or death, 0.63; 95% 
CI, 0.51 to 0.77). Results of subgroup analyses of 
progression-free survival showed a benefit in the 
majority of predefined subgroups (Fig. 2).
In patients with a tumor BRCA mutation, the 
median progression-free survival was 37.2 months 
in the olaparib group and 21.7 months in the 
placebo group (hazard ratio for disease progres-
sion or death, 0.31; 95% CI, 0.20 to 0.47) 
(Fig. 3A). In patients without a tumor BRCA mu-
tation, the median progression-free survival was 
18.9 months in the olaparib group and 16.0 
months in the placebo group (hazard ratio for 
disease progression or death, 0.71; 95% CI, 0.58 
to 0.88) (Fig. 3B).
In patients with tumors positive for HRD 
(tumor score of ≥42 on the myChoice HRD Plus 
assay or tumor BRCA mutation), the median 
progression-free survival was 37.2 months in the 
olaparib group and 17.7 months in the placebo 
group (hazard ratio for disease progression or 
death, 0.33; 95% CI, 0.25 to 0.45) (Fig. 3C). In 
patients with HRD-positive tumors that did not 
have BRCA mutations, the median progression-
free survival was 28.1 months in the olaparib 
group and 16.6 months in the placebo group 
(hazard ratio for disease progression or death, 
0.43; 95% CI, 0.28 to 0.66) (Fig. 3D).
In patients with HRD-negative tumors or 
whose tumor HRD status was unknown (total, 
419 patients), the median progression-free sur-
vival was 16.9 months in the olaparib group and 
16.0 months in the placebo group (hazard ratio 
for disease progression or death, 0.92; 95% CI, 
0.72 to 1.17) (Fig. S3A). In patients with HRD-
negative tumors (277 patients), the median pro-
gression-free survival was 16.6 months in the 
olaparib group and 16.2 months in the placebo 
group (hazard ratio for disease progression or 
Figure 1. Kaplan–Meier Estimates of Investigator-Assessed Progression-free Survival.
Shown are Kaplan–Meier estimates of the rate of freedom from disease progression, as assessed by investigators, 
and from death. According to Kaplan–Meier estimates, the percentage of patients in the olaparib-plus-bevacizumab 
group and the placebo-plus-bevacizumab group who were free from disease progression and death was 78% and 
66%, respectively, at 12 months; 62% and 46%, respectively, at 18 months; and 46% and 28%, respectively, at 24 
months. The dashed horizontal line indicates the median value.
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death, 1.00; 95% CI, 0.75 to 1.35) (Fig. S3C). 
(Data for patients whose tumor HRD status was 
unknown are shown in Fig. S3B.)
The median time until the first subsequent 
treatment for all patients was 24.8 months in the 
olaparib group and 18.5 months in the placebo 
Figure 2. Subgroup Analysis of Progression-free Survival.
All subgroups presented here were predefined, except for two post hoc subgroups: homologous-recombination deficiency (HRD) nega-
tive or unknown and HRD unknown. The outcome of first-line treatment at screening was determined according to the electronic case-
report form. For the hazard ratios, the size of the circle is proportional to the number of events. The gray band represents the 95% con-
fidence interval for the overall population, and the dashed line indicates the point of no effect. CA-125 denotes cancer antigen 125, CR 
complete response, ECOG Eastern Cooperative Oncology Group, FIGO International Federation of Gynecology and Obstetrics, NED no 
evidence of disease, PR partial response, and ULN upper limit of the normal range.
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group (hazard ratio, 0.59; 95% CI, 0.49 to 0.71). 
In an interim analysis of second progression–
free survival (data maturity, 39%), the Kaplan–
Meier estimate of the rate of freedom from sec-
ond disease progression and death at 18 months 
was 79% in the olaparib group and 80% in the 
placebo group (hazard ratio, 0.86; 95% CI, 0.69 
to 1.09) (Fig. S4). Overall survival data are im-
mature.
Safety
The median duration of the randomized inter-
vention was 17.3 months (range, 0.0 to 33.0) for 
olaparib and 15.6 months (range, 0.1 to 26.2) for 
placebo. The median duration of treatment with 
bevacizumab since randomization was 11.0 
months (range, 0.7 to 21.4) in the olaparib group 
and 10.6 months (range, 0.7 to 17.1) in the pla-
cebo group.
The most common adverse events and the 
incidence of associated grade 3 or higher adverse 
events for the entire maintenance treatment pe-
riod are shown in Table 2 and Table S5. The most 
common adverse events (all grades) that occurred 
at a higher incidence among patients receiving 
olaparib plus bevacizumab than among those 
receiving placebo plus bevacizumab were fatigue, 
nausea, and anemia (Table 2). The most com-
mon adverse event (all grades) that occurred at a 
higher incidence among patients receiving place-
bo plus bevacizumab than among those receiv-
ing olaparib plus bevacizumab was hypertension 
(Table 2). Serious adverse events occurred in 31% 
of the patients in both trial groups (Table S6). 
The most common serious adverse event that 
occurred at a higher incidence with olaparib plus 
bevacizumab than with placebo plus bevaci-
zumab was anemia (34 patients [6%] in the 
olaparib group and 1 patient [<1%] in the pla-
cebo group). The most common serious adverse 
event that occurred at a higher incidence with 
placebo plus bevacizumab than with olaparib 
plus bevacizumab was hypertension (35 patients 
[13%] in the placebo group and 48 patients [9%] 
in the olaparib group). Fatal adverse events oc-
curred during the trial intervention or up to 30 
days after discontinuation of the intervention in 
1 of 535 patients (<1%) in the olaparib group and 
in 4 of 267 patients (1%) in the placebo group. 
(Details of serious and fatal adverse events are 
provided in the Supplementary Appendix.)
Myelodysplastic syndromes, acute myeloid leu-
kemia, or aplastic anemia occurred in 6 of 535 
patients (1%) receiving olaparib plus bevacizu-
mab and in 1 of 267 patients (<1%) receiving 
placebo plus bevacizumab. New primary cancers 
occurred in 7 of 535 patients (1%) in the olapa-
rib group and in 3 of 267 patients (1%) in the 
placebo group. Grade 1 or 2 pneumonitis, inter-
stitial lung disease, or bronchiolitis occurred in 
6 patients (1%) in the olaparib group and no 
patients in the placebo group.
Adverse events were usually managed by dose 
modification rather than discontinuation (Ta-
ble 2). The most common adverse events leading 
to discontinuation of olaparib were anemia and 
nausea (Table S7).
Adverse events occurring only in the time 
period when bevacizumab was being adminis-
tered as maintenance therapy are summarized in 
Table S8. Adverse events of special interest for 
bevacizumab (e.g., hypertension) are shown in 
Table S9.
Health-Related Quality of Life
The mean global health status–quality of life 
score at baseline was 68.6 in the olaparib group 
and 67.1 in the placebo group. The adjusted mean 
change from baseline was −1.33 points (95% CI, 
−2.47 to −0.19) in the olaparib group (498 patients) 
and −2.89 points (95% CI, −4.52 to −1.26) in the 
placebo group (246 patients) (Fig. S5). The esti-
mated between-group difference was 1.56 points 
(95% CI, −0.42 to 3.55). None of these changes 
were considered to be clinically significant.
Discussion
In the phase 3 PAOLA-1 trial, we evaluated main-
tenance therapy with the PARP inhibitor olapa-
rib as compared with placebo in patients with 
newly diagnosed advanced ovarian cancer who 
were receiving chemotherapy and bevacizumab 
followed by bevacizumab. The trial met its pri-
mary objective by showing a significant progres-
sion-free survival benefit in the intention-to-
treat population. The PAOLA-1 population was 
representative of the majority of patients with 
advanced ovarian cancer because patient selec-
tion was not restricted on the basis of surgical 
outcome or BRCA mutation status.
Prespecified subgroup analyses showed a 
progression-free survival benefit with olaparib 
in patients with BRCA-mutated and HRD-positive 
tumors. The results in patients with HRD-posi-
tive tumors without a BRCA mutation (comprising 
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nearly 20% of the PAOLA-1 population, which is 
broadly consistent with expectations)10 identify 
another patient population who had a substan-
tial clinical benefit from olaparib. A benefit was 
also seen in patients whose tumor HRD status 
was unknown, such as those with failed tests or 
insufficient tumor samples.
In this trial, the progression-free survival bene-
fit seen with olaparib plus bevacizumab in patients 
with BRCA-mutated tumors (hazard ratio for dis-
ease progression or death, 0.31; 95% CI, 0.20 to 
0.47) is consistent with that observed in the 
SOLO1 trial (hazard ratio, 0.30; 95% CI, 0.23 to 
0.41),8 despite the improved outcome of the con-
trol group in our trial (median progression-free 
survival, 21.7 months with placebo plus bevacizu-
mab in the PAOLA-1 trial and 13.8 months with 
placebo in the SOLO1 trial), which may be due 
to the addition of bevacizumab or to differences 
in patient selection.22 Caution is needed when 
comparing outcomes between patients in the 
SOLO1 trial and patients with BRCA-mutated 
tumors in the PAOLA-1 trial because of differ-
ences between the two trials, including in base-
line characteristics (Table S3). Patients in the 
PAOLA-1 trial had a higher disease burden, with 
a lower percentage of patients undergoing up-
front cytoreductive surgery (51%, vs. 63% in the 
SOLO1 trial) and a higher percentage of patients 
having residual macroscopic disease after cyto-
reductive surgery (35% vs. 22%) and stage IV 
disease (30% vs. 17%).
The lack of a maintenance olaparib mono-
therapy comparator group is a limitation of the 
PAOLA-1 trial, making it difficult to conclude 
whether the progression-free survival benefit 
seen in patients with HRD-positive tumors with-
out BRCA mutations (who were not included in 
the SOLO1 trial) was due largely to the addition 
of olaparib or whether a synergistic effect oc-
curred with olaparib and bevacizumab. Accord-
ing to preclinical data, hypoxia that is induced 
by an antiangiogenic treatment can induce, or 
at least increase, HRD,23 which means that beva-
cizumab may increase the activity of olaparib in 
patients with HRD-positive tumors and, in par-
ticular, patients with HRD-positive tumors with-
out a BRCA mutation; this hypothesis requires 
further exploration. Data regarding second pro-
gression–free survival and overall survival are 
currently immature. Although HRD subgroup 
analyses were prespecified, they were not part of 
the multiple-testing procedure for this trial.
The safety profile of the olaparib group in the 
PAOLA-1 trial was generally consistent with that 
reported for olaparib in the SOLO1 trial8 and in 
patients with relapsed disease (phase 3 SOLO2 
trial),24 with the notable exception of hyperten-
sion, a frequent toxic effect of bevacizumab, 
which was more common in the PAOLA-1 trial. 
The addition of olaparib to bevacizumab did not 
increase the known toxic effects associated with 
bevacizumab.
The incidence of myelodysplastic syndromes, 
acute myeloid leukemia, or aplastic anemia 
among patients with newly diagnosed disease in 
the PAOLA-1 trial (1% in the olaparib group and 
<1% in the placebo group) was similar to that 
reported in the SOLO1 trial8 and in trials involv-
ing patients with relapsed disease.12,13,24,25 Greater 
understanding and prospective registries are 
needed to determine the characteristics of pa-
tients at risk for these rare, but potentially fatal, 
hematologic disturbances.
Neither trial group had a clinically significant 
change in health-related quality of life. There 
Figure 3 (facing page). Kaplan–Meier Estimates of 
 Investigator-Assessed Progression-free Survival, 
 According to Tumor BRCA Mutation Status and 
 Homologous-Recombination Deficiency (HRD) Status.
Among the patients with a tumor BRCA mutation (pre-
specified subgroup analysis) (Panel A), the Kaplan–
Meier estimate of the percentage of patients who were 
free from disease progression and death at 24 months 
was 76% in the olaparib-plus-bevacizumab group and 
39% in the placebo-plus-bevacizumab group. Among 
the patients without a tumor BRCA mutation (prespec-
ified subgroup analysis) (Panel B), the Kaplan–Meier 
estimate of the percentage of patients who were free 
from disease progression and death at 24 months was 
33% in the olaparib-plus-bevacizumab group and 23% 
in the placebo-plus-bevacizumab group. Among the 
patients with HRD-positive tumors, as defined by a 
 tumor HRD score of 42 or higher or a tumor BRCA 
 mutation (prespecified subgroup analysis) (Panel C), 
the Kaplan–Meier estimate of the percentage of pa-
tients who were free from disease progression and death 
at 24 months was 66% in the olaparib-plus-bevacizumab 
group and 29% in the placebo-plus-bevacizumab group. 
Among the patients with HRD-positive tumors without 
a BRCA mutation (prespecified subgroup analysis) 
(Panel D), the Kaplan–Meier estimate of the percent-
age of patients who were free from disease progression 
and death at 24 months was 52% in the olaparib-plus-
bevacizumab group and 26% in the placebo-plus-beva-
cizumab group. Tumor HRD status was determined for 
82% of the tumor samples.
n engl j med 381;25 nejm.org December 19, 20192426
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
was no evidence of a meaningful difference in 
health-related quality of life between the trial 
groups.
Administering maintenance olaparib in addi-
tion to bevacizumab to patients with newly diag-
nosed advanced ovarian cancer who were receiv-
ing standard treatment including bevacizumab 
resulted in a significant progression-free survival 
benefit, with a substantial benefit in patients 
with HRD-positive tumors. Previously defined 
toxic effects of olaparib and bevacizumab were 
noted, and rare serious hematologic and mild-to-
moderate pulmonary toxic effects also occurred.
A data sharing statement provided by the authors is available 
with the full text of this article at NEJM.org.
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Event
Olaparib plus Bevacizumab 
(N = 535)
Placebo plus Bevacizumab 
(N = 267)
All Grades Grade ≥3 All Grades Grade ≥3
number (percent)
Any 531 (99) 303 (57) 256 (96) 136 (51)
Fatigue or asthenia 283 (53) 28 (5) 86 (32) 4 (1)
Nausea 285 (53) 13 (2) 58 (22) 2 (1)
Hypertension 245 (46) 100 (19) 160 (60) 81 (30)
Anemia† 219 (41) 93 (17) 27 (10) 1 (<1)
Lymphopenia‡ 126 (24) 38 (7) 25 (9) 3 (1)
Arthralgia 116 (22) 3 (1) 64 (24) 4 (1)
Vomiting 117 (22) 8 (1) 29 (11) 5 (2)
Abdominal pain 103 (19) 8 (1) 53 (20) 5 (2)
Diarrhea 98 (18) 12 (2) 45 (17) 5 (2)
Neutropenia§ 95 (18) 32 (6) 42 (16) 8 (3)
Leukopenia¶ 95 (18) 10 (2) 26 (10) 4 (1)
Urinary tract infection 79 (15) 1 (<1) 27 (10) 1 (<1)
Headache 73 (14) 2 (<1) 36 (13) 2 (1)
Constipation 53 (10) 0 28 (10) 1 (<1)
Thrombocytopenia‖ 42 (8) 9 (2) 9 (3) 1 (<1)
Proteinuria 31 (6) 5 (1) 40 (15) 1 (<1)
Leading to dose interruption 291 (54) NA 65 (24) NA
Leading to dose reduction 220 (41) NA 20 (7) NA
Leading to discontinuation of intervention 109 (20) NA 15 (6) NA
*  Data are shown for adverse events that occurred in at least 10% of the patients in either trial group (except where noted)
during the trial intervention or up to 30 days after discontinuation of the intervention. The adverse events were graded
according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. NA denotes
not available.
†  The data include patients with anemia, a decreased hemoglobin level, a decreased hematocrit, a decreased red-cell count, 
erythropenia, macrocytic anemia, normochromic anemia, normochromic normocytic anemia, or normocytic anemia.
‡  The data include patients with a decreased lymphocyte count, lymphopenia, a decreased B-lymphocyte count, or a de-
creased T-lymphocyte count.
§  The data include patients with neutropenia, febrile neutropenia, neutropenic sepsis, neutropenic infection, a decreased
neutrophil count, idiopathic neutropenia, granulocytopenia, a decreased granulocyte count, or agranulocytosis.
¶  The data include patients with leukopenia or a decreased white-cell count.
‖  Thrombocytopenia occurred in less than 10% of the patients in each trial group, but the data are provided to complete 
the profile of hematologic toxic effects. The data include patients with thrombocytopenia, decreased platelet production, 
a decreased platelet count, or a decreased plateletcrit.
Table 2. Adverse Events with Olaparib or Placebo in Patients Also Receiving Bevacizumab.*
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